Document Detail


The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia.
MedLine Citation:
PMID:  8544635     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Botulinum toxin type A (BOTOX) injection of the thyroarytenoid muscle is used to control speech symptoms in patients with adductor spasmodic dysphonia. Transient difficulty in swallowing liquids is a common treatment side effect. Laryngeal movement durations were measured during swallowing in 13 adductor spasmodic dysphonia patients undergoing treatment and in 6 normal control subjects in order to determine the following: 1. whether, prior to the injection, laryngeal movement durations were longer in the spasmodic dysphonia patients than in the control subjects; 2. whether movement durations increased following the injections; 3. whether preinjection swallowing difficulties related to postinjection swallowing measurements and postinjection patient reports of swallowing problems. A piezoelectric movement transducer was shown to be accurate for noninvasive measurement of laryngeal movement duration in relation to muscle onset and offset for hyoid elevation and relaxation. Before botulinum toxin type A injection, no significant differences in swallowing duration were found between the patient and control groups. Four patients with swallowing complaints prior to injection had longer laryngeal movement durations than the other spasmodic dysphonia patients and the control subjects. Following injection, laryngeal movement durations increased in the patients with spasmodic dysphonia, and eight patients reported dysphagia for an average of 2 weeks. Relationships were found between the patients' initial reports of swallowing problems and increased laryngeal movement durations before and after botulinum toxin type A injection. Those patients initially reporting swallowing difficulties had severe dysphagia for 2 weeks after the injection. Patient reports of dysphagia prior to injection may indicate a greater likelihood of significant dysphagia following thyroarytenoid injection with botulinum toxin type A.
Authors:
S E Holzer; C L Ludlow
Related Documents :
7963375 - 24-hour ph monitoring in symptomatic patients without erosive esophagitis who did not r...
6601435 - Adenocarcinoma of the esophagus in patients with scleroderma.
15085025 - Association of schatzki ring with eosinophilic esophagitis in children.
20533065 - Relationship between manometric findings and reported symptoms in nutcracker esophagus:...
11527485 - Cognitive impairment and mortality in older primary care patients.
20620095 - Proteomic profiling of cerebrospinal fluid in parkinsonian disorders.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Laryngoscope     Volume:  106     ISSN:  0023-852X     ISO Abbreviation:  Laryngoscope     Publication Date:  1996 Jan 
Date Detail:
Created Date:  1996-02-13     Completed Date:  1996-02-13     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8607378     Medline TA:  Laryngoscope     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  86-92     Citation Subset:  IM    
Affiliation:
Voice and Speech Section, National Institute on Deafness and Other Communication Disorders, Bethesda, MD 20892, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Botulinum Toxins / administration & dosage*,  adverse effects*
Deglutition Disorders / chemically induced*,  physiopathology
Electromyography
Female
Humans
Injections, Intramuscular
Larynx / drug effects,  physiology
Male
Middle Aged
Movement
Spasm / complications
Voice Disorders / drug therapy*
Chemical
Reg. No./Substance:
0/Botulinum Toxins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tracheal neovascularization: a method involving mobilization of a complete tracheal neovascularized ...
Next Document:  Vocal capacities in esophageal and tracheoesophageal speakers.